Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Antidiabetic Agents (original) (raw)

1.Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95.

2.Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-85.

3.Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, inci-dence, and outcomes. Hepatology 2016;64:73-84.

4.Kim KS, Lee BW, Kim YJ, Lee DH, Cha BS, Park CY. Nonalcoholic fatty liver disease and diabetes: part II: treatment. Diabetes Metab J 2019;43:127-43.

5.Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-90.

6.Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB. Clinical trial: pilot study of metformin for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2009;29:172-82.

7.Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011;305:1659-68.

8.Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Biomed Rep 2013;1:57-64.

9.Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307.

10.Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Die- hl AM, Bass NM. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-85.

11.Musso G, Cassader M, Paschetta E, Gambino R. Thi-azolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med 2017 177:633-40. Erratum in: JAMA Intern Med 2017; 177:747.

12.Choung S, Joung KH, You BR, Park SK, Kim HJ, Ku BJ. Treatment with lobeglitazone attenuates hepatic steatosis in diet-induced obese mice. PPAR Res 2018;2018:4292509.

13.Lee YH, Kim JH, Kim SR, Jin HY, Rhee EJ, Cho YM. Lobeglitazone, a novel thiazolidinedione, improves nonalcoholic fatty liver disease in type 2 diabetes: its efficacy and predictive factors related to responsiveness. J Korean Med Sci 2017;32:60-9.

14.Hur KY, Moon MK, Park JS, Kim SK, Lee SH, Yun JS. 2021 Clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association. Diabetes Metab J 2021;45:461-81.

15.Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R. Liraglutide safety and efficacy in patients with nonalcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016;387:679-90.

16.Kuchay MS, Krishan S, Mishra SK, Choudhary NS, Singh MK, Wasir JS. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia 2020;63:2434-45.

17.Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V. A placebo-controlled trial of subcutane-ous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021;384:1113-24.

18.Hartman ML, Sanyal AJ, Loomba R, Wilson JM, Nikoo-ienejad A, Bray R. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care 2020;43:1352-5.

19.Kato H, Nagai Y, Ohta A, Tenjin A, Nakamura Y, Tsuki-yama H. Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes. diabetes Res Clin Pract 2015;109:199-205.

20.Cui J, Philo L, Nguyen P, Hofflich H, Hernandez C, Bet-tencourt R. Sitagliptin vs. placebo for nonalcoholic fatty liver disease: a randomized controlled trial. J Hepatol 2016;65:369-76.

21.Fukuhara T, Hyogo H, Ochi H, Fujino H, Kan H, Naeshi-ro N. Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. Hepatogastroenterology 2014;61:323-8.

22.Macauley M, Hollingsworth KG, Smith FE, Thelwall PE, Al-Mrabeh A, Schweizer A. Effect of vildagliptin on hepatic steatosis. J Clin Endocrinol Metab 2015;100:1578-85.

23.Mashitani T, Noguchi R, Okura Y, Namisaki T, Mitoro A, Ishii H. Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes. Biomed Rep 2016;4:183-7.

24.Eriksson JW, Lundkvist P, Jansson PA, Johansson L, Kvar-nström M, Moris L. Effects of dapagliflozin and n-3 carboxylic acids on nonalcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia 2018;61:1923-34.

25.Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). diabetes Care 2018;41:1801-8.

26.Cusi K, Bril F, Barb D, Polidori D, Sha S, Ghosh A. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes Metab 2019;21:812-21.

27.Ito D, Shimizu S, Inoue K, Saito D, Yanagisawa M, Inukai K. Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care 2017;40:1364-72.

28.Han E, Lee YH, Lee BW, Kang ES, Cha BS. Ipragliflozin additively ameliorates nonalcoholic fatty liver disease in patients with type 2 diabetes controlled with metformin and pioglitazone: a 24-week randomized controlled trial. J Clin Med 2020;9:259.